Silver Book Fact

New Medicines in Development for Parkinson’s Disease in 2018

Fact image

America's Biopharmaceutical Companies. Medicines in Development for Neurological Disorders: 2018 Report. Washington, D.C.: PhRMA; 2018. https://www.phrma.org/report/medicines-in-development-for-neurological-disorders-2018-report. Accessed June 11, 2019

Reference

Title
Medicines in Development for Neurological Disorders: 2018 Report
Publication
PhRMA
Publisher
PhRMA
Publication Date
2018
Authors
America's Biopharmaceutical Companies
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • A study of Parkinson’s disease treatments found that pramipexole is a cost-effective treatment for early and advanced Parkinson’s disease. The total cost-effectiveness ratio was $8,837/QALY for patients with early Parkinson’s…  
  • Around 75 – 100 experimental therapies that are aimed at slowing or stopping the progression of Alzheimer’s disease are currently in clinical trials.  
  • If an Alzheimer’s disease treatment breakthrough that delayed the age of onset by 5 years was introduced in 2015, by 2050 Medicare costs for people with the disease would be…  
  • The present value QUALY gains associated with a new drug that by 2010 could delay disease onset by 1, 3, and 5 years. The dollar value estimates range from approximately…  
  • If an Alzheimer’s disease treatment breakthrough that delayed the age of onset by 5 years was introduced in 2015, by 2020 total cost of care (for all payers) for all people…